A computer system may receive pharmacy information associated with a second computer system, where the pharmacy information specifies, for a potential prescription transaction for a prescription, a cost for an individual, an overhead associated with an entity when the potential prescription transaction is facilitated by the entity, and a residual amount. Then, the computer system may assess whether there is a prescription-transaction advantage when a second potential prescription transaction for the prescription is facilitated by the second entity. When there is the prescription-transaction advantage, the computer system may dynamically optimize or tailor a second cost for the individual and a second residual amount associated with the second potential prescription transaction. Next, the computer system may provide comparison information associated with the second potential prescription transaction addressed to the second computer system, where the comparison information specifies the second cost and the second residual amount.

A computer system may receive pharmacy information associated with a second computer system, where the pharmacy information specifies, for a potential prescription transaction for a prescription, a cost for an individual, an overhead associated with an entity when the potential prescription transaction is facilitated by the entity, and a residual amount. Then, the computer system may assess whether there is a prescription-transaction advantage when a second potential prescription transaction for the prescription is facilitated by the second entity. When there is the prescription-transaction advantage, the computer system may dynamically optimize or tailor a second cost for the individual and a second residual amount associated with the second potential prescription transaction. Next, the computer system may provide comparison information associated with the second potential prescription transaction addressed to the second computer system, where the comparison information specifies the second cost and the second residual amount.

A process to securely store and manage patient healthcare information. The patient provides some information that is available to selected healthcare providers thereby avoiding repeating the same information to each treating healthcare provider. Healthcare providers may also store information about the patient on the system to make that information available to other treating healthcare providers. The information is owned by the patient and is portable with the patient.

A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.

A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.

A pain management system for treating pain and/or detecting potential drug abuse in a patient suffering from pain, the system comprising at least one human machine interface (HMI), operable to acquire data generated by a patient responsive to pain that the patient experiences and data responsive to the patients intake of a drug for controlling the pain; at least one processor operable to process the pain and drug intake data to generate a pain control regimen; and at least one communication interface operable to support communications between an attending medical professional and the at least one HMI and/or the processor to enable the attending medical professional to access the pain and drug intake data and the pain control regimen

A pain management system for treating pain and/or detecting potential drug abuse in a patient suffering from pain, the system comprising at least one human machine interface (HMI), operable to acquire data generated by a patient responsive to pain that the patient experiences and data responsive to the patients intake of a drug for controlling the pain; at least one processor operable to process the pain and drug intake data to generate a pain control regimen; and at least one communication interface operable to support communications between an attending medical professional and the at least one HMI and/or the processor to enable the attending medical professional to access the pain and drug intake data and the pain control regimen

Devices, systems, and methods for localized delivery of a chemotherapy, hormonal therapy, or targeted drug/biologic therapy to a target tissue area of an internal body organ of a patient. Computer systems may be used for planning and navigation in super selective drug delivery via a tracheobronchial airway. A catheter may be used to form a sealed treatment chamber in a natural lumen extending through the target tissue area. Air is purged from the chamber, which is then filled with a liquid drug solution for an adequate treatment session time, solution volume and drug concentration to saturate the target tissue area, thereby providing the treatment. The liquid drug solution may be circulated or recirculated through the chamber or maintained stationary therewithin to saturate the target tissue area. The chamber is evacuated at the end of the treatment session.

Diabetes analysis system for analysis and interpretation of data related to glucose level (GL) in blood. The system includes an input module to receive GL related data from measurements of interstitial fluid in subcutaneous tissue, and a hypoglycemia identification module to identify hypoglycemic events by performing a computer-implemented automatic search of the received GL related data. All uninterrupted glucose levels less than a predetermined level in a same time series are considered as one hypoglycemic event. A hypoglycemia classification module analyzes, for each identified event, the glucose data during a predetermined first time period preceding the hypoglycemic event, to determine the glucose level during the first time period. The hypoglycemia classification module determines the type of hypoglycemia event, based upon the glucose level during the first time period, by applying a computer-implemented pattern search procedure on a predetermined hypoglycemic classification scheme, in order to identify the underlying cause of hypoglycemia.

Features relating to a medical station are provided. The medical station includes collection points and channels for collection and diversion of materials. The medical station includes a base and an upper module, where the upper module is configured to cover a processing device and provide work areas for access and use of the processing device. The upper module, consistent with implementations of the current subject matter, includes recesses and channels for collecting spilled materials to prevent the spilled materials damaging critical components.